|
US2021038543A1
|
|
Kit for preparing injectable carmustine solutions
|
|
CA3057479A1
|
|
Improved kit for preparing injectable carmustine solutions
|
|
US2020108010A1
|
|
Kit for preparing injectable carmustine solutions
|
|
CA3109440A1
|
|
Stable ready-to-use carmustine pharmaceutical composition
|
|
CA3095890A1
|
|
Carmustine formulation
|
|
WO2019077507A1
|
|
Process for preparation of lanreotide acetate
|
|
WO2019016692A1
|
|
Particle size stabilization of protein bound particles and methods thereof
|
|
US2019367443A1
|
|
Process for preparation of isoproterenol hydrochloride
|
|
US2019298671A1
|
|
Lipid formulations of carmustine
|
|
CA3029584A1
|
|
Process for preparation of icatibant acetate
|
|
WO2017212390A1
|
|
Process for lanreotide acetate preparation
|
|
WO2017178950A1
|
|
Process for preparation of lanreotide acetate
|
|
WO2017182908A1
|
|
Pharmaceutical compositions of apixaban
|
|
WO2017175107A1
|
|
Process for preparation of octreotide acetate
|
|
WO2017149469A1
|
|
Heterocyclic compounds useful as ido and/or tdo modulators
|
|
EP3400226A1
|
|
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
|
EP3408252A1
|
|
Process for preparation of prostacyclin derivatives
|
|
WO2017125841A1
|
|
Pharmaceutical compositions of teriflunomide
|
|
WO2017098392A1
|
|
Sterile parenteral suspensions
|
|
EP3350154A1
|
|
An improved process for preparation of trientine dihydrochloride
|
